In a recent interview with PharmaShots, William F. Doyle, Executive Chairman at Novocure shared information about the company's activities in the field of glioblastoma and mesothelioma. He also discussed the company's technology, Tumor Treating Fields (TTFields), and its potential for broad applicability across solid tumors.
Shots:
Novocure is a global oncology company working to extend survival…
In a recent interview with PharmaShots, Andrea Taylor, Researcher at Launch And Scale Speedometer shared her insights and highlights on data how rich countries shopping spree for COVID-19 vaccines means fewer vaccinations for billions in low-income countries
Shots:
The Launch and Scale Speedometer project aims to systematically analyze the factors that support or hinder the introduction and scaling of interventions,…
In a recent interview with PharmaShots, Julie Foster, Vice President, Global Customer Experience of the Diabetes business at Medtronic, shares information about recent and upcoming announcements for the company.
Shots:
The integration of real-time CGM data into the smart insulin pen app follows the acquisition of Companion Medical's InPen to the Medtronic portfolio, as of Sept'2020
The…
In a recent interview with PharmaShots, Dr. Spetzler, President and Chief Scientific Officer of Caris Life Sciences shared his insights and highlights on the launch of CODEai.
Shots:
CODEai is a real-world clinico-genomic data platform that integrates Caris Life Sciences extensive catalog of molecular data with cancer treatment information and clinical outcomes data for ~215,000…
In a recent interview with PharmaShots, Aidan Foley, Chairman and Chief Executive Officer of True Digital Surgery shared his insights and highlights on data of the Aesculap Aeos Robotic Digital Microscope.
Shots:
The robotic digital microscope enables surgeons to execute precision movements in neurosurgery, spine, and ear, nose, and throat operations, through a multi-axis robotic arm.
The platform utilizes…
In a recent interview with PharmaShots, Doug Fambrough, Ph.D., President and CEO of Dicerna shares his insights and highlights on data of Nedosiran presented at ASN Week 2020.
Shots:
All participants regardless of PH subtype, achieved normal or near-normal Uox excretion @day180, 92% participants (100% & 67% with PH1 & PH2) achieved normal Uox excretion…
In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Mirikizumab.
Shots:
@52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the SC…
In a recent interview with PharmaShots, Andrea Stancati, Vice President, Head GI Global Medical Franchise shares his insights and highlights of Entyvio (vedolizumab)
Shots:
The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE 2 (CD)…
In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit.
Shots:
QIAGEN to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA viruses
The…
In a recent interview with PharmaShots, Dr. Lotus Mallbris, the Vice President of Immunology Development at Eli Lilly shares her insights and highlights on Baricitinib.
Shots:
If approved, Baricitinib could be the first JAK inhibitor in the EU for adults with moderate to severe AD. EC's decision is expected in the next one-two months.
Lilly is evaluating Baricitinib for SLE, for which…

